Pipeline
Timelines & milestones
Combatting Antimicrobial Resistance and Diseases with High Unmet Medial Needs
Our OMV technology has demonstrated an excellent safety profile in a Phase I clinical trial, is administration route-agnostic, scalable and stable over years. See our diversified pipeline of high impact programs for more information.
ADA
Status
Phase I concluded with positive results.
Information:
Adjuvants are vital ingredients used in vaccinology for enhancing the strength and duration of immune protection. AdJane has developed its own adjuvants, ADA-24 for intramuscular administration and ADA-25 for intranasal administration, based on its proprietary OMV-Vacc platform technology.
BEA
Status
Commencing on 2 challenge studies and tox. batch manufacturing
Information:
Gonorrhea is a major global public health concern and recognized as a priority pathogen by the WHO. It is one of the most common yet disruptive diseases worldwide, with nearly 100 million cases reported annually and potentially severe health consequences like infertility, neonatal blindness, and increased risk of HIV infection.
CARA
Status
Commencing tox. batch manufacturing
Information:
HFMD is one of the most common childhood diseases, particularly in Southeast Asia, the USA, and Australia. Despite the availability of several vaccines, infection rates and severe cases continue to rise due to limited strain coverage, leading to incomplete immunity, reinfections, and ongoing outbreaks. In severe cases, HFMD can cause neurological complications, respiratory issues, organ failure, and death.